Literature DB >> 22825024

Childhood urticaria.

Nadine Marrouche1, Clive Grattan.   

Abstract

PURPOSE OF REVIEW: The present article reviews childhood urticaria. It provides an update on the current understanding of its pathophysiology and highlights the current practice in the management of this condition. RECENT
FINDINGS: Progress has been made in understanding the pathophysiology of urticaria with the elucidation of an autoimmune basis in a significant proportion of children with chronic spontaneous urticaria. H1-antihistamines remain the mainstay of therapy, but there is increasing awareness on the risks of sedating first-generation antihistamines. Omalizumab is increasingly being used off-license in the most refractory cases.
SUMMARY: Urticaria is a common disease that affects children and adults. However, paediatric urticaria has specific features and remains poorly understood. Acute spontaneous urticaria is the most common clinical presentation in childhood. It is caused by viral infection in most cases with an identifiable trigger. By contrast, chronic spontaneous urticaria in children may be autoimmune, but more studies are needed to understand the clinical significance of functional autoantibodies in this subgroup of patients. Investigations should always be guided by history. Treatment remains largely symptomatic. H1-antihistamines are the mainstay of therapy but are insufficient to control symptoms in all patients. There is an urgent need for more efficacious therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22825024     DOI: 10.1097/ACI.0b013e3283574cb3

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  7 in total

Review 1.  Pharmacologic Management of Chronic Urticaria in Pediatric Patients: The Gap Between Guidelines and Practice.

Authors:  Paul V Williams
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

2.  Management of chronic urticaria in children: a clinical guideline.

Authors:  Carlo Caffarelli; Francesco Paravati; Maya El Hachem; Marzia Duse; Marcello Bergamini; Giovanni Simeone; Massimo Barbagallo; Roberto Bernardini; Paolo Bottau; Filomena Bugliaro; Silvia Caimmi; Fernanda Chiera; Giuseppe Crisafulli; Cristiana De Ranieri; Dora Di Mauro; Andrea Diociaiuti; Fabrizio Franceschini; Massimo Gola; Amelia Licari; Lucia Liotti; Carla Mastrorilli; Domenico Minasi; Francesca Mori; Iria Neri; Aurelia Pantaleo; Francesca Saretta; Carlo Filippo Tesi; Giovanni Corsello; Gian Luigi Marseglia; Alberto Villani; Fabio Cardinale
Journal:  Ital J Pediatr       Date:  2019-08-15       Impact factor: 2.638

3.  Natural History and Influencing Factors of Chronic Urticaria in Children.

Authors:  Hyeon A Kim; Myung Chul Hyun; Bong Seok Choi
Journal:  Allergy Asthma Immunol Res       Date:  2022-01       Impact factor: 5.764

Review 4.  The challenges of chronic urticaria part 2: Pharmacological treatment, chronic inducible urticaria, urticaria in special situations.

Authors:  Mario Sánchez-Borges; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan Bernstein; Giorgio Walter Canonica; Motohiro Ebisawa; R Maximiliano Gomez; Sandra González-Diaz; Bryan Martin; Mário Morais de Almeida; Jose Antonio Ortega Martell
Journal:  World Allergy Organ J       Date:  2021-06-03       Impact factor: 4.084

5.  Interleukin 1-β, interleukin-1 receptor antagonist, and interleukin 18 in children with acute spontaneous urticaria.

Authors:  E Machura; M Szczepańska; B Mazur; M Barć-Czarnecka; A Kasperska-Zając
Journal:  Biomed Res Int       Date:  2013-12-29       Impact factor: 3.411

6.  Basophil markers for identification and activation in the indirect basophil activation test by flow cytometry for diagnosis of autoimmune urticaria.

Authors:  Zehwan Kim; Bong Seok Choi; Jong Kun Kim; Dong Il Won
Journal:  Ann Lab Med       Date:  2016-01       Impact factor: 3.464

Review 7.  Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue.

Authors:  A V Marzano; N Cassano; G Genovese; C Moltrasio; G A Vena
Journal:  Br J Dermatol       Date:  2020-07-05       Impact factor: 11.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.